2025 India Attention-Deficit Hyperactivity Disorder Revenue Opportunities Report
Description
The 2025 India Attention-Deficit Hyperactivity Disorder Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Attention-Deficit Hyperactivity Disorder by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market in India include Sun Pharmaceutical Industries, Cipla, Glenmark Pharmaceuticals, and Lupin Limited. These Indian pharmaceutical giants offer a range of ADHD medications and hold significant market presence domestically. Glenmark Pharmaceuticals, notably, is expanding into the US ADHD drug market, indicating its active role in ADHD therapeutics development and commercialization. These firms cater to the growing demand due to rising ADHD diagnosis rates in India and contribute to the market projected to grow from $538 million in 2022 to nearly $1.2 billion by 2030 with a CAGR of 10.5%.
International companies such as Eli Lilly and Company, Novartis AG, Johnson & Johnson, and Pfizer Inc. also participate actively in India’s ADHD therapeutics space either through direct operations or partnerships with Indian firms. Their global presence and product portfolios, including well-known brands like Ritalin, Adderall, and Strattera, bolster treatment options available to Indian patients. The combined efforts of domestic and multinational companies are driving advancements in stimulant and non-stimulant ADHD treatments in India, responding to increased awareness and demand for effective therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Attention-Deficit Hyperactivity Disorder by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Attention-Deficit Hyperactivity Disorder (ADHD) therapeutics market in India include Sun Pharmaceutical Industries, Cipla, Glenmark Pharmaceuticals, and Lupin Limited. These Indian pharmaceutical giants offer a range of ADHD medications and hold significant market presence domestically. Glenmark Pharmaceuticals, notably, is expanding into the US ADHD drug market, indicating its active role in ADHD therapeutics development and commercialization. These firms cater to the growing demand due to rising ADHD diagnosis rates in India and contribute to the market projected to grow from $538 million in 2022 to nearly $1.2 billion by 2030 with a CAGR of 10.5%.
International companies such as Eli Lilly and Company, Novartis AG, Johnson & Johnson, and Pfizer Inc. also participate actively in India’s ADHD therapeutics space either through direct operations or partnerships with Indian firms. Their global presence and product portfolios, including well-known brands like Ritalin, Adderall, and Strattera, bolster treatment options available to Indian patients. The combined efforts of domestic and multinational companies are driving advancements in stimulant and non-stimulant ADHD treatments in India, responding to increased awareness and demand for effective therapies.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
